Lyra Therapeutics to Participate in Upcoming Investor Conferences
06 September 2023 - 10:00PM
Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage
biotechnology company developing innovative therapies for the
localized treatment of chronic rhinosinusitis (CRS), today
announced that Maria Palasis, Ph.D., President and Chief Executive
Officer, will participate in the following investor conferences in
September:
- H.C.
Wainwright 25th Annual Global Investment Conference –
Fireside chat on Wednesday, September 13th at 2:00 p.m. ET
- Cantor
Global Healthcare Conference 2023 – Fireside chat on
Tuesday, September 26th at 4:20 p.m. ET
Live webcast of the presentations will be
available on the Investor Relations section of the Company's
website at investors.lyratherapeutics.com. Replays of the webcasts
will be available for 30 days following the presentation.
About Lyra
TherapeuticsLyra Therapeutics, Inc. is a clinical-stage
biotechnology company developing long-acting anti- inflammatory
therapies for the localized treatment of patients with chronic
rhinosinusitis (CRS). Lyra has two investigational product
candidates, LYR-210 and LYR-220, in late-stage development for CRS,
a highly prevalent inflammatory disease of the paranasal sinuses
which leads to debilitating symptoms and significant morbidities.
LYR-210 and LYR-220 are bioresorbable nasal implants designed to be
inserted in a simple, in-office procedure and are intended to
deliver six months of continuous mometasone furoate drug therapy
(7500µg MF) to the sinonasal passages. LYR-210 is designed for
surgically naïve patients and is being evaluated in the ENLIGHTEN
Phase 3 clinical program, while LYR-220, an enlarged implant, is
being evaluated in the BEACON Phase 2 clinical trial in patients
who have recurrent symptoms despite prior ethmoid sinus surgery.
These two product candidates are designed to treat the estimated
four million CRS patients in the United States who fail medical
management each year. For more information, please visit
www.lyratx.com and follow us on LinkedIn.
Contact Information:
Ellen Cavaleri, Investor Relations
615.618.6228
ecavaleri@lyratx.com
Lyra Therapeutics (NASDAQ:LYRA)
Historical Stock Chart
From Apr 2024 to May 2024
Lyra Therapeutics (NASDAQ:LYRA)
Historical Stock Chart
From May 2023 to May 2024